YieldMax AI & Tech Portfolio Option Income ETF vs Regeneron Pharmaceuticals Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $41.68, while Regeneron Pharmaceuticals Inc trades at $675.7 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals.
| GPTY | REGN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $812.27 |
52-Week Low | $34.73 | $542.52 |
Market Cap | — | $69.66B |
Enterprise Value | — | $63.61B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.
Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →